Bookbuilding IPO | ₹29 Cr | Listed at NSE SME | Wed, Nov 13, 2024 - Mon, Nov 18, 2024
Onyx Biotec IPO is a book build issue of ₹29.34 crores. The issue is entirely a fresh issue of 0.48 crore shares of ₹29.34 crore.
Onyx Biotec IPO bidding started from Nov 13, 2024 and ended on Nov 18, 2024. The allotment for Onyx Biotec IPO was finalized on Nov 19, 2024. The shares got listed on NSE SME on Nov 22, 2024.
Onyx Biotec IPO price band is set at ₹61 per share. The lot size for an application is 2,000. The minimum amount of investment required by an retail is ₹1,22,000 (2000 shares) (based on upper price). The minimum lot size for investment in HNI is 2 lots (4,000 shares), amounting to ₹2,44,000.
Horizon Management Pvt.Ltd. is the book running lead manager and MAS Services Ltd. is the registrar of the issue. The Market Maker of the company is Giriraj Stock Broking Pvt.Ltd..
Refer to Onyx Biotec IPO RHP for detailed Information.
IPO Open
Wed, Nov 13, 2024
IPO Close
Mon, Nov 18, 2024
Issue Price
₹61 per share
Market Cap (Pre-IPO)
₹110.61 Cr
| IPO Date | 13 to 18 Nov, 2024 |
| Listed on | Fri, Nov 22, 2024 |
| Face Value | ₹10 per share |
| Price Band | ₹58 to ₹61 |
| Issue Price | ₹61 per share |
| Lot Size | 2,000 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 48,10,000 shares (agg. up to ₹29 Cr) |
| Reserved for Market Maker | 2,44,000 shares Giriraj Stock Broking Pvt.Ltd. (agg. up to ₹1 Cr) |
| Fresh Issue (Ex Market Maker) | 45,66,000 shares (agg. up to ₹28 Cr) |
| Net Offered to Public | 45,66,000 shares (agg. up to ₹28 Cr) |
| Share Holding Pre Issue | 1,33,22,200 shares |
| Share Holding Post Issue | 1,81,32,200 shares |
| NSE Symbol | ONYX |
| ISIN | INE0WVU01018 |
Onyx Biotec IPO comprises a total issue size of 48,10,000 shares. The net offer to the public is 45,66,000 shares, after excluding 2,44,000 shares allotted on a firm basis. Of the Net offer 22,78,000 (49.89%) are allocated to QIB, 6,88,000 (15.07%) allocated to NII 16,00,000 (35.04%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 22,78,000 | 49.89% | 47.36% |
| − Anchor Investor Shares Offered | 13,66,000 | 28.40% | |
| − QIB (Ex. Anchor) Shares Offered | 9,12,000 | 18.96% | |
| NII (HNI) Shares Offered | 6,88,000 | 15.07% | 14.30% |
| Retail Shares Offered | 16,00,000 | 35.04% | 33.26% |
| Firm Reservations | |||
| Market Maker Shares Offered | 2,44,000 | 5.07% | |
| Total Shares Offered | 48,10,000 | 100.00% | 100.00% |
Investors can bid for a minimum of 2,000 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 2,000 | ₹1,22,000 |
| Retail (Max) | 1 | 2,000 | ₹1,22,000 |
| HNI (Min) | 2 | 4,000 | ₹2,44,000 |
Onyx Biotec IPO raises ₹8.33 crore from anchor investors. Onyx Biotec IPO Anchor bid date is November 12, 2024.
📝 Anchor Investors Letter (PDF)
| Bid Date | Tue, Nov 12, 2024 |
| Shares Offered | 13,66,000 |
| Anchor Portion (₹ Cr.) | 8.33 |
| Anchor lock-in period end date for 50% shares (30 Days) | Thu, Dec 19, 2024 |
| Anchor lock-in period end date for remaining shares (90 Days) | Mon, Feb 17, 2025 |
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets.
The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.
The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.
As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies.
The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited.
As of July 31, 2024, the company has 175 employees across various departments.
| Period Ended | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 74.77 | 74.14 | 58.72 | 36.84 |
| Total Income | 10.54 | 53.87 | 39.62 | 44.98 |
| Profit After Tax | 1.31 | 3.03 | 1.84 | 3.35 |
| NET Worth | 26.19 | 24.88 | 18.20 | 16.38 |
| Reserves and Surplus | 12.86 | 11.56 | 12.30 | 10.47 |
| Total Borrowing | 31.56 | 30.78 | 29.23 | 12.24 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use; | 6.08 |
| 2 | Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections; | 1.24 |
| 3 | Prepayment or repayment of all or a portion of certain loans availed by the Company; and | 12.00 |
| 4 | General Corporate Purposes | 6.00 |
| KPI | May 31, 2024 |
|---|---|
| ROE | 4.99% |
| ROCE | 3.71% |
| Debt/Equity | 1.21 |
| RoNW | 4.99% |
| PAT Margin | 12.42% |
| Price to Book Value | 3.10 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 2.28 | 4.33 |
| P/E (x) | 26.81 | 14.1 |
| Promoter Holding | 88.6% | 65.1% |
| Market Cap | ₹110.61 Cr. |
The Onyx Biotec IPO is subscribed 198 times on November 18, 2024 6:20:00 PM (Day 3). The public issue subscribed 118.26 times in the retail category, 32.49 times in the QIB category, and 602.86 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for | Total Application |
|---|---|---|---|---|
| QIB | 32.49 | 9,12,000 | 2,96,34,000 | 22 |
| NII* | 602.86 | 6,88,000 | 41,47,68,000 | 9,320 |
| Retail | 118.26 | 16,00,000 | 18,92,10,000 | 94,605 |
| Total | 198 | 32,00,000 | 63,36,12,000 | 1,03,947 |
Total Application : 1,03,947
*Market Maker portion is not included to NII/HNI.
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Issue management fees including fees and reimbursements of Market Making fees and payment to other Intermediaries such as Legal Advisors to the IPO, Registrars and other out of pocket expenses. | 1.26 |
| 2 | Marketing and Selling Commission and expenses | 2.45 |
| 3 | Advertising and marketing expenses | 0.16 |
| 4 | Printing and distribution of issue stationery | 0.01 |
| 5 | Listing fees | 0.01 |
| 6 | SEBI and NSE processing fees | 0.00 |
| 7 | Book Building software fees | 0.04 |
| 8 | Other regulatory expenses | 0.05 |
| 9 | Miscellaneous | 0.05 |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹61.00 |
| Open | ₹54.05 |
| Low | ₹51.45 |
| High | ₹56.75 |
| Last Trade | ₹56.75 |
Lead Manager Reports
Onyx Biotec IPO is a SME IPO of 48,10,000 equity shares of the face value of ₹10 aggregating up to ₹29 Crores. The issue is priced at ₹61 per share. The minimum order quantity is 2000.
The IPO opens on Wed, Nov 13, 2024, and closes on Mon, Nov 18, 2024.
MAS Services Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Onyx Biotec IPO using UPI as a payment gateway. Zerodha customers can apply in Onyx Biotec IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Onyx Biotec IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Onyx Biotec IPO opens on Wed, Nov 13, 2024 and closes on Mon, Nov 18, 2024.
Onyx Biotec IPO lot size is 2000, and the minimum amount required for application is ₹1,22,000.
You can apply in Onyx Biotec IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Onyx Biotec IPO will be done on Tuesday, November 19, 2024, and the allotted shares will be credited to your demat account by Wed, Nov 20, 2024. Check the Onyx Biotec IPO allotment status.
The Onyx Biotec IPO listing date is on Fri, Nov 22, 2024.
